78210
document
The effect of Naftidrofuryl on ethanol-induced liver damage in chronic alcoholic patients . A prospective double-blind placebo-controlled trial of intramuscular Naftidrofuryl was carried out on 32 randomly selected hospitalized male alcoholic patients with clinical , biochemical and histological evidence of hepatic damage . Seventeen patients received the drug ( 40 mg in 5 ml i.m . three times daily for 6 days ) and 15 patients received a placebo ( 5 ml in normal saline i.m . three times daily for 6 days ) . The drug was well tolerated and there were no adverse side-effects . Naftidrofuryl significantly improved the physiological function of the liver cells as reflected by indocyanine green ( ICG ) clearance by the liver ( t = 2.61 ; p less than or equal to 0.02 ) and also caused a larger fall in raised serum levels of gamma glutamyl transpeptidase ( GGT ) than did the placebo injections . Overall clinical improvement ( e.g . appetite , body weight , reduced liver size , general sense of well-being ) was more clearly evident in patients of the treated group than in those of the placebo group . Naftidrofuryl , therefore , appears to be of benefit in ethanol-induced liver damage and more extensive long-term trials are suggested in patients with alcoholic liver disease ( ALD ) .
78211
Intervention_Pharmacological
Naftidrofuryl
78212
Intervention_Control
placebo-controlled
78213
Intervention_Pharmacological
Naftidrofuryl
78214
Intervention_Control
placebo
78215
Intervention_Pharmacological
Naftidrofuryl
78216
Outcome_Adverse-effects
adverse side-effects .
78217
Outcome_Physical
physiological function of the liver cells as reflected by indocyanine green ( ICG ) clearance
78218
Outcome_Physical
serum levels of gamma glutamyl transpeptidase ( GGT )
78219
Outcome_Physical
clinical improvement ( e.g . appetite
78220
Outcome_Physical
body weight
78221
Outcome_Physical
reduced liver size
78222
Outcome_Physical
general sense of well-being
78223
Participant_Condition
chronic alcoholic
78224
Participant_Sample-size
32
78225
Participant_Sex
male
78226
Participant_Condition
alcoholic
78227
Participant_Condition
hepatic damage
78228
Participant_Condition
ethanol-induced liver damage
78229
Participant_Condition
alcoholic liver disease ( ALD )